Metastatic Colon Cancer
33
5
6
12
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
9.1%
3 terminated out of 33 trials
80.0%
-6.5% vs benchmark
12%
4 trials in Phase 3/4
33%
4 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (33)
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
Curcumin in Combination With 5FU for Colon Cancer
CALM: Managing Distress in Malignant Brain Cancer
xDRIVE in Metastatic Colorectal Cancer
Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
Detection of Brain Metastasis by MRI in Metastatic Colorectal Cancer Patients
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
Development of Clinical and Biological Database in Colorectal Cancer
Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer
ZETA : Prospective Observational Study
REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
Pembrolizumab + Poly-ICLC in MRP Colon Cancer
Liver Embolization Approaches for Tumor Management
PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer
Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial